降尿酸化合物的活性评价方法研究进展OA北大核心CSTPCD

Hyperuricemia is a metabolic disease caused by elevated uric acid in the body,and is closely related to the increased risk of cardiovascular disease,metabolic disorders,and renal complications.In the development process of uric acid-lowering drugs,activity evaluation is a crucial step.At present,the activity screening methods of uric acid-lowering drugs can be roughly divided into two categories:in vitro and in vivo.In vitro screening is mainly for such targets as xanthine oxidase,urate transporters,and purine nucleoside phosphorylase,etc.;while in vivo screening is achieved by rodent,poultry and organoid models.In this article,the activity evaluation methods for uric acid-lowering compounds are comprehensively summarized both in vitro and in vivo,aiming to provide some insight for the development of uric acid-lowering drugs.